Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Christian Blank on Combining Immunotherapy Agents in High-Risk Melanoma

Christian Blank, MD, PhD
Published: Tuesday, Nov 08, 2016



Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma. The results were presented at the 2016 Society for Melanoma Research (SMR) Annual Meeting. 

In early findings from the trial, the overall response rate (ORR) was 80% with the combination of nivolumab and ipilimumab. Additionally, 30% of patients treated with the neoadjuvant combination experienced a pathologic complete response (pCR). 

Blank noted that he is interested in following up with these patients to see if they relapse. With the possible successful outcomes down the line, this combination may shift the landscape for how high-risk melanoma is treated.

<<< View more from the 2016 SMR Annual Meeting


Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma. The results were presented at the 2016 Society for Melanoma Research (SMR) Annual Meeting. 

In early findings from the trial, the overall response rate (ORR) was 80% with the combination of nivolumab and ipilimumab. Additionally, 30% of patients treated with the neoadjuvant combination experienced a pathologic complete response (pCR). 

Blank noted that he is interested in following up with these patients to see if they relapse. With the possible successful outcomes down the line, this combination may shift the landscape for how high-risk melanoma is treated.

<<< View more from the 2016 SMR Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x